sucroferric oxyhydroxide

(redirected from Velphoro)

sucroferric oxyhydroxide

(soo-kroe-fer-ik ox-ee-hye-drox-ide),


(trade name)


Therapeutic: electrolyte modifiers
Pharmacologic: phosphate binders
Pregnancy Category: B


Control of elevated serum phosphorous levels in patients with chronic renal disease currently on dialysis.


Binds dietary phosphorous in the GI tract via ligand exchange.

Therapeutic effects

Decreased serum phosphorous levels and sequelae of hyperphosphatemia.


Absorption: Phosphate binding is local with no systemic absorption. Minimal amounts of released iron may be absorbed.
Distribution: Unknown.
Metabolism and Excretion: Action is local, no metabolism. Bound phosphate is excreted in feces.
Half-life: Unknown.

Time/action profile (phosphorous lowering)

POwithin 4 wk12–16 wklength of treatment


Contraindicated in: None noted.
Use Cautiously in: Peritonitis (from peritoneal dialysis), significant hepatic/gastric disorders, following major GI surgery, history of hemochromatosis/diseases of iron accumulation; Obstetric: Use during pregnancy only if clearly needed; Pediatric: Safe and effective use in children has not been established.

Adverse Reactions/Side Effects


  • discolored feces (most frequent)
  • diarrhea
  • nausea
  • unpleasant taste


Drug-Drug interaction

Should not be used concurrently with oral levothyroxine or oral Vitamin D analogs due to interference with phosphorous homeostatis.May ↓ absorption and effectiveness of alendronate or doxycyline, administer 1 hr before sucroferric oxyhydroxide.


Oral (Adults) 500 mg three time daily (with meals) initially, may be titrated by 500 mg/day at weekly intervals depending on serum phosphorous, usual range is 1500–3000 mg/day in three divided doses.


Chewable tabletswildberry: 500 mg

Nursing implications

Nursing assessment

  • Monitor for abdominal pain or discomfort. Sucroferric oxyhydroxide causes discolored (black) stool and may mask GI bleeding. Medication does not effect guaiac based (Hemocult) or immunological based (iColoRectal and Hexagon Opti) fecal occult blood tests.
  • Lab Test Considerations: Monitor serum phosphorous levels and dose of sucroferric oxyhydroxide. Dose is titrated in increments of 500 mg (1 tablet) per day as needed until acceptable serum phosphorous level (≤5.5 mg/dL) is reached. Monitor periodically thereafter. May begin titration 1 wk after start of therapy and adjust at weekly intervals.
    • Monitor effect and iron homeostasis in patients with peritonitis during peritoneal dialysis, significant hepatic or gastric disorders, following major gastrointestinal surgery, or with a history of hemachromatosis or other diseases with iron accumulation.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Oral: Administer 3 times daily with meals. Tablets must be chewed; do not swallow whole. Tablets may be crushed prior to swallowing. No additional fluid is required above usual amount taken.

Patient/Family Teaching

  • Instruct patient to take medication as directed. Do not attempt to replace missed doses; resume medication with next meal; do not double doses.
  • Advise patient to avoid taking levothyroxine and vitamin D analogs during therapy and to take alendronate and doxycycline at least 1 hr before sucroferric oxyhydroxide.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected.

Evaluation/Desired Outcomes

  • Decreased serum phosphorous levels.
Drug Guide, © 2015 Farlex and Partners
Mentioned in ?
References in periodicals archive ?
Velphoro grew by 126.6% to CHF 81.1 million, driven by strong US growth as a result of continued adoption of updated KDIGO (Kidney Disease Improving Global Outcomes) Guidelines
Our joint company Vifor Fresenius Medical Care Renal Pharma (VFMCRP), the cornerstone of our ambition to become the world's leading pharmaceutical company in the field of nephrology, enjoyed robust growth, supported by the success of Velphoro in the US.
M2 EQUITYBITES-January 29, 2015-Vifor Pharma receives approval from Swiss agency for Velphoro
Vifor Pharma, an international pharmaceutical company, has received approval from the Swiss agency for Therapeutic Products (Swissmedic) for Velphoro, it was reported yesterday.
M2 PHARMA-January 29, 2015-Vifor Pharma receives approval from Swiss agency for Velphoro
M2 PHARMA-December 3, 2013-Vifor Pharma receives approval for Velphoro from US Food and Drug Administration
Vifor Pharma, a company in the Galenica Group, has received approval for the hyperphosphatemia drug, Velphoro, from the US Food and Drug Administration for the control of serum phosphorus levels in patients with Chronic Kidney Disease on dialysis, it was reported yesterday.
M2 EQUITYBITES-December 3, 2013-Vifor Pharma receives approval for Velphoro from US Food and Drug Administration